Background. We describe changes in rates of cervical intraepithelial neoplasia grades 2, 3 and adenocarcinoma in situ (CIN2+) during a period of human papillomavirus (HPV) vaccine uptake and changing cervical cancer screening recommendations.
In the United States, human papillomavirus (HPV) vaccination has been recommended for adolescent females aged 11-12 years since 2006 [1] . The vaccination series can be started at 9 years of age, and is also recommended through 26 years of age for those not vaccinated previously. The uptake of the vaccine has been gradual, with regional variation [2] [3] [4] [5] . Nationally, the proportion of women aged 19-26 who had ever received at least 1 dose of the HPV vaccine increased from 10.5% in 2008 to 40.2% in 2014 [5] . Through 2014, 99% of all vaccine doses given were the quadrivalent vaccine [6] .
The impact of the vaccination program on HPV-associated cancers may not be observed for decades, given the long natural history of HPV infection and carcinogenesis. Several efforts to monitor the vaccine's impact have evaluated outcomes evident soon after infection occurs that can be used as early endpoints. They include assessing the prevalence of vaccine-type infections at genital sites, either in the general population [7] [8] [9] or in women undergoing cervical cancer screening [10] , and the monitoring of genital warts diagnoses [11, 12] . Additional monitoring efforts target intermediate outcomes, such as highgrade cervical lesions or precancers that typically take years to develop and that are detected through cervical cancer screening [13] [14] [15] .
In the years since the HPV vaccine was introduced, the US cervical cancer screening recommendations have changed multiple times [16] [17] [18] , complicating the interpretation of population trends in cervical precancers. In 2012, most major medical organizations recommended delaying an initial screening to 21 years, regardless of age at sexual debut, and screening at longer intervals (every 3 years or, in women aged at least 30 years, every 5 years if high-risk HPV testing is performed in addition to cytology) [17] . These guidelines were designed to avoid unnecessary procedures in women with lesions that have a high probability of regressing without treatment [17] . As a consequence of fewer women being screened annually, fewer cervical lesions are expected to be detected. Thus, it is difficult to determine whether any decreases in the rates of cervical lesions in the population represent the vaccine's impact or the results of fewer women receiving annual screenings. Considering that only screened women are at risk of having a lesion detected, using the number of women screened each year as the denominator in incidence rate calculations is a viable approach to controlling for the impact of changing screening guidelines [13, 14, [19] [20] [21] [22] .
The HPV Vaccine Impact Monitoring Project (HPV-IMPACT) was established to monitor the incidence of high-grade cervical lesions, including cervical intraepithelial neoplasia (CIN) grades 2 and 3 and adenocarcinoma in situ (AIS; together referred to as CIN2+), in catchment areas within 5 geographically-dispersed states. A prior report on HPV-IMPACT cases from 2008-2012 documented decreases in the incidence of CIN2+ in women residing in 4 of the HPV-IMPACT catchment areas, as well as declines in screening [15] . Since that report, a fifth HPV-IMPACT site has established robust reporting for all years of surveillance, and all sites have developed methods to estimate the proportion of women screened each year. The objectives of these analyses are to describe changes in the rates of CIN2+ and cervical cytology screening in the 5 HPV-IMPACT sites from 2008-2015, and to estimate changes in the CIN2+ incidence both in the general population and among screened women.
METHODS
HPV-IMPACT is a network of surveillance sites that consists of partnerships between the Centers for Disease Control and Prevention, state health departments, and academic institutions. Surveillance sites are located in California, Connecticut, New York, Oregon, and Tennessee. Each site conducts surveillance in a catchment area in which approximately 300 000 women aged ≥18 years reside. For 3 sites (CT, NY, TN), the catchment area is a single county. For 2 sites, the catchment area is a subset of the population of 1 (CA) or 2 (OR) counties. Each site has conducted population-based laboratory surveillance for CIN2+ since 2008, as described previously [15, 23] . Briefly, all pathology laboratories serving catchment area residents report CIN2+ cases to HPV-IMPACT staff at each site. Because women may have multiple diagnostic and treatment procedures as part of a single CIN2+ case, the incidence date was defined as the date of the earliest qualifying CIN2+ diagnosis for each woman, and the final diagnosis for each case was defined as the highest-grade lesion identified within 6 months of the incidence date.
Annual population totals of women in the age groups of 18-20, 21-24, 25-29, 30-34 , and 35-39 years were obtained for each catchment area. Population denominators were based on county-level data from the Centers for Disease Control and Prevention's National Center for Health Statistics (https://www. cdc.gov/nchs/nvss/bridged_race/data_documentation.htm); for CA and OR, county estimates were adjusted for the specific catchment area using American Community Survey data.
Each site established methodology for estimating the annual cervical cancer screening utilization by age group (Supplemental Table 1 ). Although particular data sources varied, all estimates were based on counts of cervical screening tests using either insurance claims or laboratory utilization data. To estimate the number of screened women in each year, the proportion screened in each year's age stratum was multiplied by the total population of women in the corresponding group.
We analyzed the surveillance years in 4 periods of 2 years each: 2008-2009, 2010-2011, 2012-2013, and 2014-2015 . We compared the characteristics of cases, including age groups, diagnoses, races/ethnicities, insurance statuses, and vaccination histories, by site and period. For each site and across all sites, we calculated the incidence rates per 100 000 women in each age group, using population estimates as the denominator. We also estimated the incidence per 100 000 screened women in each age group, using each site's estimated number of screened women as the denominator.
CIN2+ incidence rate ratios (IRR) were calculated by comparing the incidences in the 3 latter time periods with the earliest period using Poisson regression. All analyses were stratified by age group. Analyses were repeated with the outcome restricted to the highest-grade lesions: CIN3 and AIS (CIN3/AIS). Adjustments for surveillance sites were considered because screening methods varied by site, which could have influenced observed changes in rates over time. In addition, subset analyses were conducted that excluded cases reported during the first year of the system, when some reported cases might have been initially diagnosed in 2007 (prevalent cases), to determine whether any observed declines were attributable to this surveillance artifact.
RESULTS
A total of 16 572 CIN2+ cases among women aged 18-39 years were reported in the 5 catchment areas in 2008-2015, including 5399 cases of CIN3/AIS. Characteristics of the reported cases by age group, diagnosis, race/ethnicity, insurance, and vaccination status, both overall and by 2-year surveillance periods, are detailed in Table 1 . The total number of cases declined in each 2-year period, and differences in proportions of case characteristics were observed within the reduced numbers. Case characteristics also varied significantly by surveillance site (Table 2) . New York and Oregon had the highest proportions of cases occurring in non-Hispanic Whites. Connecticut and Tennessee had the highest proportions with public insurance.
In all sites, the rates of CIN2+ per 100 000 women generally declined over time in age groups 18-20 and 21-24 ( Figure 1 ). There was no consistent pattern of rates across all sites in the 3 older age groups. The proportion of women screened also generally declined over time in all sites, although the magnitude of declines varied by site, and declines in the 30-34 and 35-39 year age groups were minimal in California. Figure 2 shows the incidence rates per 100 000 women (panel A) and per 100 000 screened women (panel B) with all sites combined, stratified by age group. Among all women (Figure 2A (Table 3 ). In Declines in the incidence of CIN2+ among young women were still observed, but were less pronounced, in analyses among estimated screened women (Table 3 As expected, the baseline rates of CIN3/AIS (ranging from 42.9 per 100 000 women in 18-20 year-olds to 181.6 per 100 000 in 25-29 year-olds) were lower than the baseline rates of CIN2+ (which ranged from 210.1 per 100 000 women in 18-20 yearolds to 584.6 per 100 000 in 21-24 year-olds; Table 4 ). Notably, the highest baseline rate of CIN3/AIS occurred in an older age group (ie, in 25-29-year-olds) than the highest baseline rate of CIN2+ (which occurred in 21-24-year-olds). The pattern of declines and increases in the rates of CIN3/AIS among the estimated screened women were similar to the rates for CIN2+ and occurred in the same age groups, although fewer differences were statistically significant, most likely owing to the smaller sample size of CIN3/AIS cases.
Adjusting for surveillance site did not result in any meaningful changes to IRRs in analyses using all women as the denominator (Tables 3 and 4 ). In the analyses using estimated screened women as the denominator, after adjusting for surveillance site, the declines in the 2 younger age groups were slightly lower in magnitude and the increases in the older age groups became more pronounced, but the direction and significance of differences did not change. Excluding data from 2008 did not meaningfully change the model results (not shown). 
DISCUSSION
In this analysis of population-based surveillance data, we found that in young women aged 18-20 and 21-24 years, the incidence of CIN2+ lesions declined significantly and markedly between 2008 and 2015. These declines were broadly consistent across the 5 surveillance sites and were observed in analyses of both all women in the population and estimated screened women, indicating that the declines are not exclusively attributable to reductions in screening and could be attributable, at least in part, to HPV vaccine impact. The impact of the US female vaccination program on various outcomes has been shown in several studies. Nationally representative survey data have been used to document declines in the prevalence of quadrivalent vaccine-type cervicovaginal HPV infections in adolescents and young women aged 14-19 and 20-24 years [8, 9] . Analyses of claims data have documented decreases in genital warts, abnormal cervical cytology, and high-grade cervical histology lesions [11, 12, 14] .
A statewide surveillance system in New Mexico that has tracked CIN diagnoses and maintained a registry of Papanicolaou testing documented declines in CIN1, CIN2, and CIN3 in young women aged 15-19 years and declines in CIN2 in women aged 20-24 years from 2007-2014 [13] . Recently, a report on cancer registry-based surveillance for CIN3 showed a downward trend among young women in Michigan, although no data on screenings were available [24] . A previous analysis of HPV-IMPACT cases from 4 sites that reported through 2012 showed declines in the youngest age groups, as well as declines in screening, although that analysis did not allow determination of the proportion of declines attributable to reductions in screening [15] . Our analysis extends those findings by showing that the incidence of CIN2+ also declined among estimated screened women in the 18-20 and 21-24 year age groups. The decreases among screened women indicate that changing screening practices are not responsible for the entirety of declining CIN2+ rates in these age groups, although performing the 11-1.61) analysis among screened women did attenuate the magnitude of declines in young women. However, in 2012, more conservative management of abnormal screening results in 21-24-year-old women was recommended, encouraging observation over colposcopy, biopsy, and treatment, and these additional measures may have contributed to the observed declines in CIN2+ incidences in young women [25] .
We also noted an increased incidence of CIN2+ among screened women in the 3 older age groups evaluated in this analysis, particularly in the analysis among screened women. Changes in screening and management recommendations, including a delayed age for a first screening, conservative management of younger women, an increased length of screening intervals, and incorporating clinical HPV testing into screening algorithms, would all be expected to result in an increased yield of CIN2+ per screening episode and an older age at an initial diagnosis [13, [25] [26] [27] [28] . Such changes occurring during the surveillance period might, in part, explain our findings of increased CIN2+ incidences among the screened women in some age groups. Continued surveillance is necessary to determine whether the observed increased rates in the largely-unvaccinated older age groups represent a shift in age at diagnosis. An alternative explanation for increased CIN2+ rates is that there has been increased exposure to HPV due to changes in sexual behavior. Some data indicate an increase in other sexually transmitted infections in the United States [29] .
A strength of HPV-IMPACT is the inclusion of 5 geographically-dispersed surveillance areas, enabling the documentation of the vaccine's impact in different regions of the United States that have varying population characteristics. Over time, in 18-20 and 21-24 year olds, declines in CIN2+ rates were evident in all sites, as were declines in the proportion screened. However, we observed heterogeneity across sites in baseline (2008) CIN2+ rates and estimated screening proportions, and some heterogeneity in crude trends over time (such as the timing of declines in case rates in some age groups), which could signal regional variations in true incidences of the disease. At baseline (2008), the CIN2+ rates were highest in Connecticut and New York and lowest in California; the differences in baseline rates were greatest in the 3 youngest age groups. We speculate that the differences in these baseline disease rates might have been impacted by population characteristics in the different catchment areas (as reflected in demographic differences among cases), differences in clinical practices (eg, screening and diagnostic practices), or variations in the sensitivity of the surveillance system by site. While catchment area estimates of vaccinations in the population are not known, national surveys have documented differences in vaccination rates by state and region, and these differences could impact differences in the timing and magnitude of reductions in CIN2+ rates [4] . This analysis has several limitations. The individual HPV-IMPACT sites had some operational differences that could result in differences in case reporting completeness and the accuracy of denominators. These include different numbers of pathology laboratories, out-of-catchment laboratories serving catchment residents, and varying reliance on manual reporting streams. The sites had different locally-available resources for estimating the proportion of women screened for cervical cancer in each year. Inaccurate site-specific screening estimates would result in underestimates or overestimates of CIN2+ rates per 100 000 screened women; however, because the methods within sites have been consistent over time, this limitation is unlikely to affect the direction of the trends observed. Adjustments for sites in statistical models did not alter the direction or significance of our findings, although it did modify the magnitude in the analyses conducted among screened women. Finally, the analysis using screened women as the denominator would be affected if there were an association between screening and vaccination in the population. If screened women are more likely than unscreened women to have been vaccinated, the analysis would overestimate vaccine impact; if screened women are less likely to be vaccinated, the analysis would underestimate vaccine impact.
In conclusion, this analysis of 8 years of active, population-based laboratory surveillance data for high-grade cervical lesions is consistent with the vaccine's expected impact in young women ages 18-20 and 21-24 years. Continued surveillance is important for monitoring the impact of HPV vaccination in the United States as vaccinated women age into older age groups and as women who received the 9-valent vaccine, introduced in 2015 in the United States [30] , and those who received a 2-dose vaccination schedule [31] reach the cervical cancer screening age.
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